{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-012063","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.529992+00:00","generated_at":"2026-05-16T03:48:45.197335+00:00","sec_items":["5.08","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"confidence":"high","headline":"Marker Therapeutics sets 2026 annual meeting for May 1; shareholder proposals due March 9","bullets":["2026 Annual Meeting scheduled for May 1, 2026, moving more than 30 days from 2025 meeting date.","Shareholder proposals under Rule 14a-8 must be received by March 9, 2026, at company's Houston offices.","Record date and meeting details to be included in the upcoming proxy statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-012063","json":"https://secwatch.observer/filing/0001104659-26-012063.json","markdown":"https://secwatch.observer/filing/0001104659-26-012063.md","text":"https://secwatch.observer/filing/0001104659-26-012063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926012063/0001104659-26-012063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465926012063/tm265663d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:48:45.197335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}